Orphan Drug Fairness Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Sep 25, 2015)
Orphan Drug Fairness Act
This bill amends the Patient Protection and Affordable Care Act (PPACA) to exclude sales of any drug or biological product approved by the Food and Drug Administration solely for rare diseases or conditions (orphan drug) from the calculation of the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.
This Act is effective as if included in PPACA.
What just happenedOct 2, 2015
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseSep 25, 2015
- Oct 2, 2015Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Sep 25, 2015IntroReferralH11100
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Sep 25, 2015IntroReferralH11100-A
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sep 25, 2015IntroReferralH11100
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Sep 25, 2015IntroReferralIntro-H
Introduced in House
- Sep 25, 2015IntroReferral1000
Introduced in House